Cargando…
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
Noonan Syndrome with Multiple Lentigines (NSML, formerly LEOPARD syndrome) is an autosomal dominant "RASopathy" disorder manifesting in congenital heart disease. Most cases of NSML are caused by catalytically inactivating mutations in the protein tyrosine phosphatase (PTP), non-receptor ty...
Autores principales: | Wang, Jianxun, Chandrasekhar, Vasanth, Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Kontaridis, Maria I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459472/ https://www.ncbi.nlm.nih.gov/pubmed/28582432 http://dx.doi.org/10.1371/journal.pone.0178905 |
Ejemplares similares
-
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017) -
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015) -
Hypertrophic cardiomyopathy in an adult patient with Noonan syndrome with multiple lentigines
por: Rivero‐García, Pamela, et al.
Publicado: (2023) -
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018) -
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
por: Nandan, Devki, et al.
Publicado: (2018)